Patent 12023325 was granted and assigned to Deciphera Pharmaceuticals on July, 2024 by the United States Patent and Trademark Office.
The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.